A5029372363- Single-cell and spatial transcriptomics
- CAR-T cell therapy research
- Telomeres, Telomerase, and Senescence
- melanin and skin pigmentation
- Histone Deacetylase Inhibitors Research
- Advanced biosensing and bioanalysis techniques
- Epigenetics and DNA Methylation
- Autophagy in Disease and Therapy
- Immunotherapy and Immune Responses
- Melanoma and MAPK Pathways
- Protein Degradation and Inhibitors
New York University Abu Dhabi
2024
University of Luxembourg
2021-2023
Therapy Induced Senescence (TIS) leads to sustained growth arrest of cancer cells. The associated cytostasis has been shown be reversible and cells escaping senescence further enhance the aggressiveness cancers. Chemicals specifically targeting senescent cells, so-called senolytics, constitute a promising avenue for improved treatment in combination with targeted therapies. Understanding how evade is needed optimise clinical benefits this therapeutic approach. Here we characterised response...
Treatment options for patients with NRAS-mutant melanoma are limited and lack an efficient targeted drug combination that significantly increases overall progression-free survival. In addition, therapy success is hampered by the inevitable emergence of resistance. A thorough understanding molecular processes driving cancer cells' escape mechanisms crucial to tailor more follow-up therapies. We performed single-cell RNA sequencing treated MEK1/2 plus CDK4/6 inhibitors decipher transcriptional...
Summary Tumor heterogeneity is the substrate for tumor evolution and linchpin of treatment resistance. Cancer cell largely attributed to distinct genetic changes within each population. However, widespread epigenome repatterning that characterizes most cancers also highly heterogenous tumors could generate cells with diverse identities malignant features. We show high levels epigenetic regulator oncogene, UHRF1, in zebrafish hepatocytes rapidly induced methylome disordering, loss...
Abstract Therapy Induced Senescence (TIS) leads to sustained growth arrest of cancer cells. The associated cytostasis has been shown be reversible and cells escaping senescence further enhance the aggressiveness cancers. Together with targeted therapeutics, senolytics, specifically targeting senescent cells, constitute a promising avenue for improved treatments. Understanding how evade is needed optimise clinical benefits this therapeutic approach. Here we characterised response three...
In 2020, metastatic melanoma accounted for 57 000 deaths worldwide and this number is estimated to almost double over the next two decades. While efficient targeted therapies are available patients carrying BRAF mutations, fewer therapeutic options approved other genetic subtypes. Targeted therapy involving combined inhibition of MEK1/2 CDK4/6 reached phase 1b/II clinical trials NRAS-mutant melanoma. However, inevitably, resistance towards these inhibitors develops. A deep understanding...